M2699
Marimastat
≥98% (HPLC), solid, MMP inhibitor
Sinónimos:
BB2516, (2S,3R)-N4-[(1S)-2,2-Dimethyl-1-[(methylamino)carbonyl] propyl]-N1,2-dihydroxy-3-(2-methylpropyl)butanediamide
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C15H29N3O5
Número CAS:
Peso molecular:
331.41
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
Marimastat, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
solid
solubility
DMSO: ≥20 mg/mL
shipped in
wet ice
storage temp.
−20°C
SMILES string
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
InChI
1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
InChI key
OCSMOTCMPXTDND-OUAUKWLOSA-N
Gene Information
—
Application
Marimastat has been used as an inhibitor of:
- metalloproteinase 2/9 (MMP2/9), to study its effects on exercise-mediated interleukin-6 (IL-6) release in mice
- metalloproteinase, to determine protease activity in Pseudomonas aeruginosa cultures
- metalloproteinase 10 (MMP10), to study its effect on monoclonal antibody H3 binding to MMP10
Biochem/physiol Actions
Marimastat is a broad spectrum matrix metalloprotease (MMP) inhibitor
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Angela Sandri et al.
Virulence, 9(1), 1008-1018 (2018-06-26)
Cystic fibrosis (CF) lung infection is a complex condition where opportunistic pathogens and defective immune system cooperate in developing a constant cycle of infection and inflammation. The major pathogen, Pseudomonas aeruginosa, secretes a multitude of virulence factors involved in host
M Ohshima et al.
Journal of dental research, 89(11), 1315-1321 (2010-08-27)
The underlying mechanism and the therapeutic regimen for the transition of reversible gingivitis to irreversible periodontitis are unclear. Since transforming growth factor (TGF)-β has been implicated in differentially regulated gene expression in gingival fibroblasts, we hypothesized that TGF-β signaling is
Vincent E de Meijer et al.
PloS one, 5(6), e11256-e11256 (2010-07-02)
Liver fibrosis is characterized by excessive synthesis of extracellular matrix proteins, which prevails over their enzymatic degradation, primarily by matrix metalloproteinases (MMPs). The effect of pharmacological MMP inhibition on fibrogenesis, however, is largely unexplored. Inflammation is considered a prerequisite and